Utrecht: The European committee that assesses veterinary medicines recommended five new products at its November meeting, including the first medicine backed under the EU limited market framework since new rules took effect in 2022. The Committee for Veterinary Medicinal Products at the European Medicines Agency, known as CVMP, met from 3 to 5 November 2026 and published its outcomes on 6 November.
The headline opinion concerns Scovella, which contains velagliflozin. The committee recommended a marketing authorisation for horses with Equine Metabolic Syndrome that does not respond to changes in husbandry and exercise. The medicine aims to reduce hyperinsulinaemia and the associated risk of laminitis, a painful and potentially crippling hoof condition. The positive opinion followed a re-examination of an earlier committee opinion from June 2026.
The European Medicines Agency says Scovella is the first product recommended under the limited market framework of Regulation (EU) 2019/6, the veterinary medicines regulation that has applied since 2022. That framework lets companies seek approval with reduced data packages for products aimed at small markets, where full development costs would otherwise block access.
Dog owners and vets will also see new veterinary medicines reach the market. The committee backed Credelio Quattro, a combination of lotilaner, moxidectin, pyrantel and praziquantel, for dogs with mixed infestations of ectoparasites, tapeworms and roundworms. It recommended Laverdia, containing verdinexor, to extend the time to disease progression in dogs with stage II, III and IV lymphoma, classed as a minor use. Nobivac PLUS DHPPi / Leptos received a positive opinion for active immunisation of dogs from six weeks of age.
Pig farmers gained a new option among veterinary medicines as well. Streptoporc provides passive immunisation of piglets through vaccinated pregnant sows and gilts against Streptococcus suis, a bacterium that causes serious disease in pig herds and can also infect people.
Beyond new products, the CVMP updated several existing veterinary medicines. It approved changes to Syvazul BTV 3 against bluetongue and to the epizootic haemorrhagic disease vaccines Hepizovac and Orbyk EHD, including a 10-hour in-use shelf life for Orbyk EHD. It added aggression as a very rare adverse event for Zenrelia, which contains ilunocitinib, and extended Credelio to cover ear mites.
The committee also responded to the bird flu threat. It recommended a one-year extension of the marketing authorisations under exceptional circumstances for the avian influenza vaccines Vaxxinact H5 and Vaxxitek HVT+IBD+H5.
Antimicrobial resistance remained high on the agenda. The CVMP adopted the fifth joint inter-agency report on antimicrobial consumption and resistance, known as JIACRA V, which covers post-COVID trends from 2022 to 2024. The ECDC, EFSA and EMA will publish it on 10 December 2026. The committee also opened a two-month consultation on revised pharmacovigilance terminology and a six-month consultation on the VICH GL49(R2) guideline, running until the end of April 2027.
Together, these decisions show how policy on veterinary medicines links animal welfare, farm resilience and human health under the One Health approach of the EU. The European Commission will now take the final decisions on the recommended authorisations.
